Tornier N.V. Sets New 1-Year High at $20.16 (TRNX)
Tornier N.V. (NASDAQ:TRNX) set a new 52-week high during mid-day trading on Wednesday, StockRatingsNetwork.com reports. The stock traded as high as $20.16 and last traded at $20.05, with a volume of 174,240 shares. The stock had previously closed at $19.61.
TRNX has been the subject of a number of recent research reports. Analysts at Barclays Capital initiated coverage on shares of Tornier N.V. in a research note to investors on Friday, October 4th. They set an “overweight” rating and a $24.00 price target on the stock. Separately, analysts at Piper Jaffray Cos. raised their price target on shares of Tornier N.V. from $22.00 to $23.00 in a research note to investors on Wednesday, August 7th. They now have an “overweight” rating on the stock. Finally, analysts at JPMorgan Chase & Co. upgraded shares of Tornier N.V. from a “neutral” rating to an “overweight” rating in a research note to investors on Wednesday, August 7th. They now have a $24.00 price target on the stock, up previously from $20.00. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $21.14.
Tornier N.V. has a 52-week low of $14.53 and a 52-week high of $19.97. The stock has a 50-day moving average of $19.38 and a 200-day moving average of $17.98. The company’s market cap is $959.0 million.
Tornier N.V. (NASDAQ:TRNX) last announced its earnings results on Tuesday, August 6th. The company reported ($0.28) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.14) by $0.14. The company had revenue of $78.10 million for the quarter, compared to the consensus estimate of $77.20 million. Tornier N.V.’s revenue was up 18.3% compared to the same quarter last year. Analysts expect that Tornier N.V. will post $-0.39 EPS for the current fiscal year.
Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.